Excision Biotherapeutics Inc.

Plus rounds for Rubedo, Flindr, Endeavor, SynOx and more

Plus: Artios hires Silverstein as CFO and updates from Astellas, atai, Cartography, Corvus and Helio

Plus RGImmune launches with F-Prime’s backing and updates from Pfizer, Tridek-One  

Small molecules lead, with antibodies, gene therapies, vaccines and nanoparticles also in the lineup

Improved antivirals, antibodies, vaccines and possible cures enter the horizon

Plus: Precigen, Transition Bio, Shoreline, Syros, Twist, Vor and more

Plus: GlycoMimetics names Semerjian as King’s successor, plus updates from Pieris, Assembly and more

Precision BioSciences Inc. (NASDAQ:DTIL) named Alex Kelly CFO. Kelly joined the gene editing company as chief corporate affairs officer in October 2020 and has served as interim CFO since

South Korea-based protein degradation play Orum Therapeutics Inc. hired Jae Won Kim as CFO. Kim was director of the healthcare investment banking team at Citi.  T cell therapy company

Mark Shearman will join Editas Medicine Inc. (NASDAQ:EDIT) in June as EVP and CSO. Shearman currently serves as CSO of Applied Genetic Technologies Corp. (NASDAQ:AGTC). Kyowa Kirin Co. Ltd.